SCHEMBL971224

SCHEMBL971224

CCOc1c(OC)cc2oc(-c3ccccc3)cc(=O)c2c1O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREB1 P16220 3/20 0.79
ABCB1 P08183 3/20 0.69
ABCG2 Q9UNQ0 2/20 0.69
FLT3 P36888 2/20 0.67
SLCO2B1 O94956 1/20 0.67
PRSS1 P07477 1/20 0.67
PRSS2 P07478 1/20 0.67
PRSS3 P35030 1/20 0.67
KDM4E B2RXH2 2/20 0.66
POLB P06746 2/20 0.66
MAPT P10636 2/20 0.66
ADORA3 P0DMS8 1/20 0.66
PTPRS Q13332 1/20 0.65
EGFR P00533 1/20 0.63
RET P07949 1/20 0.63
KDR P35968 1/20 0.63
RECQL P46063 1/20 0.62
CYP1A1 P04798 1/20 0.61
CYP1A2 P05177 1/20 0.61
OPRD1 P41143 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL971797 0.93 CREB1 (0.82) CREB1ABCB1ABCG2FLT3SLCO2B1
SCHEMBL971911 0.91 CREB1 (0.80) CREB1ABCB1ABCG2FLT3SLCO2B1
Mosloflavone SCHEMBL29477310 0.89 KDM4E (0.81) CREB1ABCB1ABCG2FLT3SLCO2B1
Mosloflavone SCHEMBL971985 0.89 KDM4E (0.81) CREB1ABCB1ABCG2FLT3SLCO2B1
SCHEMBL28106367 0.89 ABCB1 (0.67) CREB1ABCB1ABCG2FLT3SLCO2B1
SCHEMBL972514 0.88 CREB1 (1.00) CREB1ABCB1ABCG2FLT3SLCO2B1
SCHEMBL971035 0.85 ABCB1 (0.79) CREB1ABCB1ABCG2FLT3SLCO2B1
SCHEMBL15674607 0.84 ABCB1 (0.81) CREB1ABCB1ABCG2FLT3SLCO2B1
SCHEMBL718970 0.84 ABCB1 (0.81) CREB1ABCB1ABCG2FLT3SLCO2B1
SCHEMBL30152130 0.84 ABCB1 (0.81) CREB1ABCB1ABCG2FLT3SLCO2B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875650-B2 Baicalein analogs; enhances bioavailability of active compounds, especially orally administered compounds, by inhibition of P-glycoprotein 170 (P-gp 170) and/or CYP450 enzyme; 6-Acetoxy-5,7-dihydroxyflavone YALE UNIVERSITY (US) 2011-01-25 US disclosed
US-20070161605-A1 Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring YALE UNIVERSITY (US) 2007-07-12 US disclosed
WO-2005075449-A1 COMPOUNDS AND METHODS TO INCREASE ANTI-P-GLYCOPROTEIN ACTIVITY OF BAICALEIN BY ALKYLATION ON THE A RING YALE UNIVERSITY (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161605-A1 Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring ABCB1, ABCB11, ABCG2 CREB1 2524/4885ABCB1 1/4885ABCG2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.